Sepsis

AM-Pharma announces positive results in Phase IIa sepsis trial with Alkaline Phosphatase

Published in Blood Weekly, November 23rd, 2006

AM-Pharma B.V., a biopharmaceutical company engaged in the preclinical and early clinical development of novel compounds to treat infectious and inflammatory diseases, announces first positive results observed in its multicenter double blind, placebo-controlled pilot study in the treatment of sepsis with its patented Alkaline Phosphatase (AP) drug.

The study was conceived as a first pilot clinical study to assess safety of a single treatment with 200 U Alkaline Phosphatase i.v./kg in patients suffering from severe sepsis. At the same time also efficacy parameters were recorded as secondary variables.

AM-Pharma is developing a unique therapy against...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-11-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry